Jorge Sierra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1219171/publications.pdf

Version: 2024-02-01

| | | 1051969 | 1181555 | |
|----------|----------------|--------------|----------------|--|
| 18 | 3,971 | 10 | 14 | |
| papers | citations | h-index | g-index | |
| | | | | |
| | | | | |
| 18 | 18 | 18 | 5622 | |
| all docs | docs citations | times ranked | citing authors | |
| | | | | |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Prognostic impact of <i>DNMT3A</i> mutation in acute myeloid leukemia with mutated <i>NPM1</i> Blood Advances, 2022, 6, 882-890. | 2.5 | 15 |
| 2 | European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances, 2022, 6, 1193-1206. | 2.5 | 26 |
| 3 | Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: aÂcase report and review of the literature. Journal of Medical Case Reports, 2021, 15, 326. | 0.4 | 8 |
| 4 | Acute myeloid leukemia with <i>NPM1</i> mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. British Journal of Haematology, 2020, 191, 52-61. | 1.2 | 28 |
| 5 | UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Leukemia, 2020, 34, 2925-2933. | 3.3 | 6 |
| 6 | Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34); <i>DEKâ€NUP214</i> shows a favourable outcome when performed in first complete remission. British Journal of Haematology, 2020, 189, 920-925. | 1,2 | 16 |
| 7 | Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). Blood, 2020, 136, 31-32. | 0.6 | O |
| 8 | Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5â€azacytidine: Identification of responding patients. European Journal of Haematology, 2019, 103, 208-214. | 1.1 | 9 |
| 9 | Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease. Blood, 2019, 134, 289-289. | 0.6 | 2 |
| 10 | A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2394-2404. | 0.6 | 16 |
| 11 | Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value. Biology of Blood and Marrow Transplantation, 2018, 24, 55-63. | 2.0 | 33 |
| 12 | Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2511-2511. | 0.6 | 0 |
| 13 | Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2514-2514. | 0.6 | O |
| 14 | Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 2013, 121, 2734-2738. | 0.6 | 246 |
| 15 | BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Blood, 2013, 122, 2577-2577. | 0.6 | O |
| 16 | Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. Journal of Clinical Oncology, 2012, 30, 735-741. | 0.8 | 251 |
| 17 | The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Reviews Clinical Oncology, 2012, 9, 579-590. | 12.5 | 352 |
| 18 | Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 2010, 115, 453-474. | 0.6 | 2,963 |